PharmaResearch(214450) said on the 21st that it has released a renewed version of the hospital-only moisturizer "Rejuderma Ato Cream MD."
Rejuderma MD consists of "Rejuderma Ato Cream MD" and "Rejuderma Ato Lotion MD." The newly renewed Ato Cream MD is a Class 2 medical device wound dressing that forms a physical barrier to protect damaged skin barriers, such as burns or dry skin. It contains PharmaResearch's patented ingredient, Hydrolyzed DNA (c-PDRN), and is mainly used in hospitals and clinics, including dermatology and pediatrics.
The renewal focused on improving usability while maintaining the moisturizing effect of the existing product. Reflecting feedback from hospitals, clinics, and consumers, it reduced the raw materials' inherent scent and improved inconveniences that can be felt during actual use.
A PharmaResearch official said, "This renewal maintains the unique strengths of the Rejuderma MD Cream while carefully reflecting actual users' opinions," adding, "We will continue to monitor not only the product's functions but also the user-perceived experience to steadily enhance the completeness and competitiveness of Rejuderma MD products."
Meanwhile, PharmaResearch manufactures and sells pharmaceuticals, medical devices, cosmetics, and health functional foods based on regenerative medicine using DOT®PDRN and DOT®PN substances. Its flagship products include Rejuran®, Rejuven®, Conjuran®, Rejuran Cosmetic, Lian® eye drops, Rejuderma®, and Rejuvenex Cream.